Magee-Womens Hospital of UPMC
Pittsburgh, Pennsylvania, 15213, United States
NCT Number: NCT02178189
Neonatal abstinence syndrome (NAS) symptoms contribute to poor infant weight gain. Early caloric enhancement for infants exposed to methadone is inexpensive, readily available, easy to implement and could improve early outcomes for these high-risk infants. We will conduct a preliminary randomized clinical trial of high-calorie vs. standard-calorie formula for methadone exposed infants to evaluate the adequacy of recruitment, protocol feasibility and estimates of whether high-calorie formula results in more normal patterns of weight loss and gain, less severe NAS symptoms and shorter hospital stays.
Looking for future studies?
Notify Me1 day–3 day
All sexes
Interventional
Phase 2
Pittsburgh, Pennsylvania, 15213, United States
Background: Infants exposed to methadone during pregnancy experience high rates of neonatal abstinence syndrome (NAS). Common NAS symptoms (tremulousness, increased muscle tone, sweating, excessive crying, vomiting and diarrhea) increase infants' metabolic needs. Another frequent NAS symptom, weak and uncoordinated suckling, impairs infants' ability to take in adequate calories. These combined problems compromise infant weight gain. The current standard of care for opiate-exposed infants requires evidence of poor weight gain or excessive weight loss before initiating high-calorie formula. We hypothesize that inadequate caloric intake among methadone exposed infants may result in excessive weight loss, slow weight regain and exacerbation of NAS. These factors lead to the newborn's requirement for higher morphine doses and longer duration of hospitalization. Therefore, methadone exposed infants may benefit from early caloric enhancement. A nutritional intervention for opiate-exposed infants has not been previously evaluated. This application will provide data on adequacy of recruitment, protocol feasibility, performance of selected measures, and preliminary estimates of efficacy for a comprehensive R01 submission.
Specific Aims:
Design: Women on methadone will be recruited during pregnancy and will attend a single brief visit late in pregnancy. After delivery, infants will be randomized in a double blind trial of either high-calorie or standard-calorie formula which will be started at 72 hours after birth and be continued through 21 days of age. Infants will be weighed daily and will have outpatient study visits at 1 and 3 months. For this pilot study, up to 70 mothers will be enrolled over 18 months. This pilot study is needed to establish the feasibility of the study methods and to better estimate differences that can be observed between the groups. For the primary outcome variable, days until the infant returns to birth weight, discrete survival methods will be used.
Potential Impact: Early caloric enhancement for methadone-exposed infants is inexpensive, readily available, easy to implement and could improve outcomes of these high-risk infants. High-calorie formula could result in a more normal pattern of weight loss and gain, less severe NAS symptoms and shorter hospital stays.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Infants were randomized to be fed high calorie formula from 72 hours of life until age 21 days.
Infants were randomized to be fed standard calorie formula from 72 hours of life until age 21 days.
Time frame: Up to 3 weeks
Weight loss and gain patterns will include days to return to birth weight, days to weight nadir (lowest point) and maximum percent weight loss.
Time frame: Up to 3 weeks
NAS (Neonatal abstinence syndrome) severity can be measured in a few ways - for this study, we will use total length of hospital stay for NAS, duration of NAS treatment, mean Finnegan scores on days 3-10 and maximum concentration of morphine used to treat NAS
University of Pittsburgh
Other
Randomized Clinical Trial of High vs. Standard-Calorie Formula for Methadone-Exposed Infants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04419857
Chemically-Induced Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
New Haven, Connecticut, United States
View Trial DetailsNCT03918850
Chemically-Induced Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Jacksonville, Florida, United States
View Trial DetailsNCT03911739
Chemically-Induced Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Jacksonville, Florida, United States
View Trial DetailsNCT03911466
Chemically-Induced Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Jacksonville, Florida, United States
View Trial Details